Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News

Onyx stent meets DAPT performance goal in bleeding-risk patients
- Author:
- Mitchel L. Zoler, PhD
A zotarolimus-eluting coronary stent met its FDA-set performance goal in high-bleeding-risk patients on dual antiplatelet therapy for 1 month.
News

Silent brain infarcts found in 3% of AFib patients, tied to cognitive decline
- Author:
- Mitchel L. Zoler, PhD
MR-detected brain infarcts often developed in AFib patients on oral anticoagulation and in the absence of a...
News

UNTOUCHED: Inappropriate shocks cut by subcutaneous ICD improvements
- Author:
- Mitchel L. Zoler, PhD
Tweaking the filtering and programing of a subcutaneous ICD cut the inappropriate-shock rate in a classic ICD patient population.
News

Coffee drinking linked with fewer arrhythmias
- Author:
- Mitchel L. Zoler, PhD
Data from nearly 300,000 U.K. residents showed a statistically significant 3% drop in cardiac arrhythmias per...
News

FOURIER: Evolocumab follow-up shows no cognitive adverse effects
- Author:
- Mitchel L. Zoler, PhD
A cognition survey of more than 22,000 FOURIER patients showed no compromise linked to evolocumab or sharply cut LDL-C levels.
News

Hydroxychloroquine-triggered QTc-interval prolongations mount in COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
Two single-center reports further documented the incidence of QTc-interval prolongations in COVID-19 patients...
News

REPLENISH: Oral estradiol/progesterone slowed bone turnover as it cut VMS
- Author:
- Mitchel L. Zoler, PhD
A U.S. approved oral estradiol/progesterone formulation for treating vasomotor symptoms linked with significant...
News
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
- Author:
- Mitchel L. Zoler, PhD
Merck reports topline results from ertugliflozin’s FDA-mandated cardiovascular outcomes trial.
News

FDA reiterates hydroxychloroquine limitations for COVID-19
- Author:
- Mitchel L. Zoler, PhD
An FDA Safety Communication restates that hydroxychloroquine and chloroquine are only for hospitalized COVID-19 patients who can’t enter a trial...
News

AUGUSTUS: After ACS or PCI, aspirin gives AFib patients scant benefit
- Author:
- Mitchel L. Zoler, PhD
Adding aspirin to an anticoagulant and P2Y12 inhibitor showed no net benefit, even acutely, suggesting need to target aspirin to highly selected...
News

ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
A study drawing from 1,128 hypertensive, Chinese patients with COVID-19 suggested that those on an ACEI or ARB...
News

PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
- Author:
- Mitchel L. Zoler, PhD
Post hoc analyses of data from as many as 46,000 patients showed surprising links between PCSK9 inhibition and...
News

Imaging recommendations issued for COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
An expert panel organized by the Fleischner Society made recommendations on using chest radiography or CT in hospitalized COVID-19 patients.
News
Evidence suggests possible RAS-blocker benefit in COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
Animal findings and physiologic mechanisms suggest RAS system inhibitors may benefit COVID-19 patients,...
News

AHA updates management when CAD and T2DM coincide
- Author:
- Mitchel L. Zoler, PhD
Statement encourages and guides greater involvement by cardiovascular specialists in managing patients with...